Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1988 Mar;32(3):346–349. doi: 10.1128/aac.32.3.346

In vitro antimicrobial activity of tigemonam, a new orally administered monobactam.

P C Fuchs 1, R N Jones 1, A L Barry 1
PMCID: PMC172173  PMID: 3259122

Abstract

At five geographically separate medical centers, over 6,000 clinical bacterial isolates were tested for their susceptibility to tigemonam by the broth microdilution method. The antimicrobial spectrum of tigemonam was similar to that of aztreonam, but with two differences. Aztreonam was more active against Pseudomonas spp., and tigemonam was more active against some streptococci. Tigemonam was highly resistant to hydrolysis by the eight beta-lactamase enzymes tested. A significant (greater than a fourfold increase in the MICs of tigemonam) inoculum effect occurred when 3 of 13 isolates were tested with inocula of 5 X 10(5) and 1 X 10(7) CFU/ml. Tigemonam was bactericidal for all but 1 of the 13 isolates. Of the four quality-control strains recommended by the National Committee for Clinical Laboratory Standards, only Escherichia coli ATCC 25922 provided on-scale results. The proposed MIC quality-control range of tigemonam for E. coli ATCC 25922 is 0.13 to 0.5 micrograms/ml.

Full text

PDF
346

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barry A. L., Gavan T. L., Jones R. N., Ayers L. W., Fuchs P. C., Gerlach E. H., Thornsberry C. Quality control limits for microdilution susceptibility tests with aztreonam, imipenem, ceftriaxone, ceftazidime, ceftizoxime, cefuroxime, and cefonicid. Diagn Microbiol Infect Dis. 1987 May;7(1):83–87. doi: 10.1016/0732-8893(87)90076-9. [DOI] [PubMed] [Google Scholar]
  2. Barry A. L., Thornsberry C., Jones R. N., Gavan T. L. Aztreonam: antibacterial activity, beta-lactamase stability, and interpretive standards and quality control guidelines for disk-diffusion susceptibility tests. Rev Infect Dis. 1985 Nov-Dec;7 (Suppl 4):S594–S604. doi: 10.1093/clinids/7.supplement_4.s594. [DOI] [PubMed] [Google Scholar]
  3. Clark J. M., Olsen S. J., Weinberg D. S., Dalvi M., Whitney R. R., Bonner D. P., Sykes R. B. In vivo evaluation of tigemonam, a novel oral monobactam. Antimicrob Agents Chemother. 1987 Feb;31(2):226–229. doi: 10.1128/aac.31.2.226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fuchs P. C., Jones R. N., Barry A. L., Ayers L. W., Gavan T. L., Gerlach E. H. In vitro activity of carumonam (RO 17-2301), BMY-28142, aztreonam, and ceftazidime against 7,620 consecutive clinical bacterial isolates. Diagn Microbiol Infect Dis. 1986 Nov;5(4):345–349. doi: 10.1016/0732-8893(86)90041-6. [DOI] [PubMed] [Google Scholar]
  5. Jacobus N. V., Ferreira M. C., Barza M. In vitro activity of azthreonam, a monobactam antibiotic. Antimicrob Agents Chemother. 1982 Nov;22(5):832–838. doi: 10.1128/aac.22.5.832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Jones R. N., Barry A. L., Thornsberry C., Fuchs P. C., Packer R. R. The anti-microbial activity, beta-lactamase stability, and disk diffusion susceptibility testing of carumonam (RO 17-2301, AMA-1080), a new monobactam. Am J Clin Pathol. 1986 Nov;86(5):608–618. doi: 10.1093/ajcp/86.5.608. [DOI] [PubMed] [Google Scholar]
  7. Pearson R. D., Steigbigel R. T., Davis H. T., Chapman S. W. Method of reliable determination of minimal lethal antibiotic concentrations. Antimicrob Agents Chemother. 1980 Nov;18(5):699–708. doi: 10.1128/aac.18.5.699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Tanaka S. K., Summerill R. A., Minassian B. F., Bush K., Visnic D. A., Bonner D. P., Sykes R. B. In vitro evaluation of tigemonam, a novel oral monobactam. Antimicrob Agents Chemother. 1987 Feb;31(2):219–225. doi: 10.1128/aac.31.2.219. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES